Other medications commonly reported to be associated with TA-TMA include those used for graft-versus-host disease (GVHD) prophylaxis, especially the calcineurin inhibitors tacrolimus and cyclosporine, and the mammalian target of rapamycin (mTOR) inhibitor sirolimus [13]. Here, MTOR is linked to graft versus host disease.